Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC_EX:A61K39/44

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.11202011895VMUC16 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
SG 30.12.2020
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No 11202011895V Applicant INTREXON CORPORATION Inventor SABZEVARI, Helen
(54) Title: MUC16 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF a. b. C. d. FIG. 1 (57) Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders. CAR pA (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau 111111111111111111111111111111111111111III111111111111111111111111111111111111111111111111111 (10) International Publication Number WO 2019/236577 A2 (43) International Publication Date 12 December 2019 (12.12.2019) WIPO I PCT (51) International Patent Classification: C07K 16/30 (2006.01) (21) International Application Number: PCT/US2019/035384 (22) International Filing Date: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, 1E, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) with sequence listing part of description (Rule 5.2(a)) 04 June 2019 (04.06.2019) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/680,297 04 June 2018 (04.06.2018) US (71) Applicant: INTREXON CORPORATION [US/US]; 20358 Seneca Meadows Pkwy, Suite 1400, Germantown, Maryland 20876 (US). (72) Inventors: SABZEVARI, Helen; 20358 Seneca Meadows Pkwy, Suite 1400, Germantown, Maryland 20876 (US). SHAH, Rutul R.; 20358 Seneca Meadows Pkwy, Suite 1400, Germantown, Maryland 20876 (US). (74) Agent: GRANT, Angela M.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, CN11 1 1/r) N N en O 1-1 C
2.1020200139946금 나노입자-앱타머 결합체를 기반으로 하는 항체 전달체 및 이의 제조 방법
KR 15.12.2020
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No 1020190066491 Applicant 주식회사 엔이에스바이오테크놀러지 Inventor 이강석
본 발명은 금 나노입자-앱타머 결합체를 기반으로 하는 항체 전달체 및 이의 제조 방법에 관한 것으로, 본 발명에 따른 항체 전달체는 금 나노입자에 IgG Fc 도메인-특이적인 앱타머 또는 FITC-특이적인 앱타머가 결합되어 있으며, 상기 앱타머에 전달하고자 하는 항체를 특이적으로 결합하여 세포의 핵, 세포질뿐만 아니라 미토콘드리아로 항체를 효과적으로 전달할 수 있다. 또한, 매우 적은 세포독성을 갖는 금 나노입자를 이용하여 인체에 무해할 뿐만 아니라, 다양한 파장에서 빛을 반사하여 세포 내에서의 위치를 쉽게 확인할 수 있는바, 질병의 진단 또는 치료에 유용하게 이용될 수 있을 것으로 기대된다.
3.2019129803НОВЫЕ КОМБИНАЦИИ ДЛЯ АНТИГЕННОЙ ТЕРАПИИ
RU 14.12.2020
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No 2019129803 Applicant ДИАМИД МЕДИКАЛ АБ (SE) Inventor ЭССЕН-МЕЛЛЕР, Андерс (SE)
4.WO/2020/246660GOLD NANOPARTICLE-APTAMER CONJUGATE-BASED ANTIBODY DELIVERY SYSTEM, AND PREPARATION METHOD THEREOF
WO 10.12.2020
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No PCT/KR2019/011838 Applicant NES BIOTECHNOLOGY CO., LTD. Inventor LEE, Kang Seok
The present invention relates to a gold nanoparticle-aptamer conjugate-based antibody delivery system, and a preparation method thereof. In the antibody delivery system according to the present invention, a gold nanoparticle is bound to an IgG Fc domain-specific aptamer or FITC-specific aptamer, and the aptamer is specifically bound to an antibody to be delivered, so that the antibody can be effectively delivered to not only the nucleus and cytoplasm of a cell but also mitochondria thereof. In addition, the system uses the gold nanoparticle having very little cytotoxicity so as to be harmless to a human body, as well as reflects light at various wavelengths so that the position thereof within cells can be easily identified. Thus, the antibody delivery system is expected to be usefully employed in the diagnosis or treatment of diseases.
5.WO/2020/247974METHODS AND COMPOSITIONS FOR TREATING CANCER WITH COLLAGEN BINDING DRUG CARRIERS
WO 10.12.2020
Int.Class A61K 47/64
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Appl.No PCT/US2020/070113 Applicant THE UNIVERSITY OF CHICAGO Inventor HUBBELL, Jeffrey A.
This disclosure relates to tumor-targeted drug carriers that lead to improved anti-tumor efficacy by efficient delivery of a cytotoxic agent to the tumor microenvironment. Aspects of the disclosure relate to a polypeptide comprising an albumin or IgG Fc domain polypeptide operatively linked to a collagen binding domain. Further aspects relate to a composition comprising a polypeptide, nucleic acid, or cell of the disclosure.
6.111936167EGFR抗体对CD47阻断疗法的改善
CN 13.11.2020
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No 201980021372.3 Applicant 延龄草治疗公司 Inventor G·H·Y·林
使用CD47阻断剂与诸如西妥昔单抗的EGFR抗体的组合治疗诸如癌细胞的CD47+疾病细胞。在SIRPαFc的存在下,西妥昔单抗的抗癌作用得以增强。具体组合包括SIRPαFc形式,其包含作为IgG1或优选IgG4同种型的Fc。这些组合特别可用于治疗实体瘤和血液癌症,包括淋巴瘤、白血病和骨髓瘤。
7.114975MODULADORES DE MOLÉCULA PEQUEÑA DE STING HUMANA, CONJUGADOS Y APLICACIONES TERAPÉUTICAS
AR 11.11.2020
Int.Class C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
Appl.No P190101730 Applicant CURADEV PHARMA LIMITED Inventor MONALI BANERJEE
La presente se refiere a conjugados de moduladores de molécula pequeña de la proteína estimuladora de genes de interferón (STING, por sus siglas en inglés). Reivindicación 1: Un compuesto de la fórmula (1), o una sal o profármaco farmacéuticamente aceptable de este, caracterizado porque: L¹ y L² son enlazadores; T es un resto de direccionamiento; a es un entero entre 1 y 5; b es un entero entre 1 y 10; z es un entero entre 1 y 5; y C un compuesto de fórmula (2); donde X¹ es CR¹ o N; X² es CR² o N; X³ es CR³ o N; Q es C=O, S=O, SO₂, C=S o CR⁴R⁵; L es alquilo C₁₋₆ sustituido opcionalmente, polifluoroalquilo C₁₋₃, cicloalquilo C₃₋₆ sustituido opcionalmente, alquenilo C₂₋₆ sustituido opcionalmente, alquinilo C₂₋₆ sustituido opcionalmente, C=O, S=O, SO₂, -CH₂C(O)-, -CH₂CONH- o -CONH-; Y es alquilo C₁₋₆ sustituido opcionalmente, polifluoroalquilo C₁₋₃ sustituido opcionalmente, alquenilo C₂₋₆ sustituido opcionalmente, alquinilo C₂₋₆ sustituido opcionalmente, cicloalquilo C₃₋₆ sustituido opcionalmente o un heterociclo mono o bicíclico de 3 a 8 miembros sustituido opcionalmente; cada uno de R¹, R² y R³ se selecciona independientemente del grupo que consiste en H, halógeno, CN, hidroxilo, COOH, CONR¹R², NR¹R², NHCOR¹ alquilo C₁₋₆ sustituido opcionalmente, polifluoroalquilo C₁₋₃ sustituido opcionalmente, alquilsulfonilo C₁₋₆ sustituido opcionalmente, cicloalquilo C₃₋₆ mono o bicíclico sustituido opcionalmente, alquenilo C₂₋₆ sustituido opcionalmente, alquinilo C₂₋₆ sustituido opcionalmente, alcoxi C₁₋₆ sustituido opcionalmente, grupo alcoxicarbonilo C₁₋₆ sustituido opcionalmente, arilo C₅₋₁₀ mono o bicíclico sustituido opcionalmente, heteroarilo de 5 a 10 miembros mono o bicíclico sustituido opcionalmente, heterociclo de 3 a 8 miembros mono o bicíclico sustituido opcionalmente, ariloxi sustituido opcionalmente, heteroariloxi sustituido opcionalmente y heterocicliloxi sustituido opcionalmente; cada uno de R⁴ y R⁵ se selecciona independiente del grupo que consiste en H, halógeno, alquilo C₁₋₆ sustituido opcionalmente y cicloalquilo C₃₋₆ sustituido opcionalmente; o R⁴ y R⁵ juntos con el átomo al cual se unen forman un anillo espirocíclico; R⁶ es un anillo sustituido opcionalmente con uno o más grupos R¹², donde el anillo se selecciona del grupo que consiste en arilo C₅₋₁₀ mono o bicíclico; un heteroarilo mono o bicíclico de 5 a 10 miembros; cicloalquilo C₃₋₆; y un heterociclo mono o bicíclico de 3 a 8 miembros; R⁷ es H, alquilo C₁₋₆ sustituido opcionalmente, sulfonilo sustituido opcionalmente, alquilsulfonilo C₁₋₆ sustituido opcionalmente, cicloalquilo C₃₋₆ sustituido opcionalmente, alquenilo C₂₋₆ sustituido opcionalmente o alquinilo C₂₋₆ sustituido opcionalmente; R⁸ es un arilo C₅₋₁₀ mono o bicíclico sustituido opcionalmente, un heteroarilo de 5 a 10 miembros mono o bicíclico sustituido opcionalmente, cicloalquilo C₃₋₆ mono o bicíclico sustituido opcionalmente o un heterociclo de 3 a 8 miembros mono o bicíclico sustituido opcionalmente; cada uno de R⁹ y R¹⁰ se selecciona independientemente del grupo que consiste en alquilo C₁₋₆ sustituido opcionalmente, H, halógeno, CN, CO₂H, CONR¹R², azido, sulfonilo, polifluoroalquilo C₁₋₃, tioalquilo C₁₋₆ sustituido opcionalmente, alquilosulfonilo C₁₋₆ sustituido opcionalmente, cicloalquilo C₃₋₆ sustituido opcionalmente, alquenilo C₂₋₆ sustituido opcionalmente, alquinilo C₂₋₆ sustituido opcionalmente, alcoxi C₁₋₆ sustituido opcionalmente, alcoxicarbonilo C₁₋₆ sustituido opcionalmente, arilo C₅₋₁₀ mono o bicíclico sustituido opcionalmente, heteroarilo de 5 a 10 miembros mono o bicíclico sustituido opcionalmente, heterociclo sustituido opcionalmente, ariloxi sustituido opcionalmente, y heteroariloxi sustituido opcionalmente; o R⁹ y R¹⁰ juntos con el átomo de C al cual están unidos pueden combinarse para formar un anillo espirocíclico sustituido opcionalmente; R¹¹ se selecciona del grupo que consiste en alquilo C₁₋₆ sustituido opcionalmente, H, hidroxilo, polifluoroalquilo C₁₋₃, tioalquilo C₁₋₆ sustituido opcionalmente, alquilosulfonilo C₁₋₆ sustituido opcionalmente, cicloalquilo C₃₋₆ sustituido opcionalmente, alquenilo C₂₋₆ sustituido opcionalmente, alquinilo C₂₋₆ sustituido opcionalmente, alcoxi C₁₋₆ sustituido opcionalmente, alcoxicarbonilo C₁₋₆ sustituido opcionalmente, arilo C₅₋₁₀ mono o bicíclico sustituido opcionalmente, heteroarilo de 5 a 10 miembros mono o bicíclico sustituido opcionalmente, heterociclo sustituido opcionalmente, ariloxi sustituido opcionalmente, y heteroariloxi sustituido opcionalmente; el o cada grupo R¹² se selecciona independientemente del grupo que consiste en halo, OH, SH, OP(O)(OH)₂, NR¹³R¹⁴, CONR¹³R¹⁴, CN, COOR¹³, NO₂, azido, SO₂R¹³, OSO₂R¹³, NR¹³SO₂R¹⁴, NR¹³C(O)R¹⁴, O(CH₂)ₙOC(O)R¹³, NR¹³(CH₂)ₙOC(O)R¹⁴, OC(O)R¹³, OC(O)OR¹⁴, OC(O)NR¹³R¹⁴, OC(O)O(CH₂)ₙCOOR¹⁴, OC(O)NR¹³(CH₂)ₙCOOR¹⁴, alquilo C₁₋₆ sustituido opcionalmente, alcoxi C₁₋₆ sustituido opcionalmente, ariloxi sustituido opcionalmente, heteroariloxi sustituido opcionalmente, arilo C₅₋₁₀ mono o bicíclico sustituido opcionalmente, un heteroarilo de 5 a 10 miembros mono o bicíclico sustituido opcionalmente, cicloalquilo C₃₋₆ sustituido opcionalmente y un heterociclo de 3 a 8 miembros mono o bicíclico sustituido opcionalmente; cada uno de R¹³ y R¹⁴ se selecciona independientemente del grupo que consiste en H, alquilo C₁₋₆ sustituido opcionalmente, cicloalquilo C₃₋₆ mono o bicíclico sustituido opcionalmente, arilo C₅₋₁₀ mono o bicíclico sustituido opcionalmente, heteroarilo de 5 a 10 miembros mono o bicíclico sustituido opcionalmente y heterociclo de 3 a 8 miembros mono o bicíclico sustituido opcionalmente; y n es un entero entre 0 y 6; o un complejo, sal, solvato, forma tautomérica o forma polimórfica farmacéuticamente aceptable de estos.
8.10828356Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US 10.11.2020
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No 16410627 Applicant David Gordon Bermudes Inventor David Gordon Bermudes

Bacterial strains are provided having at least one of a reduced size, a sialic acid coat, inducibly altered surface antigens, and expression of PD-L1 or CTLA-4 antagonists and/or tryptophanase. The bacteria may have improved serum half-life, increased penetration into tumors, increased tumor targeting and increased antitumor activity. The bacteria are useful for delivery of therapeutic agents that treat of neoplastic diseases including solid tumors and lymphomas.

9.20200345855COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
US 05.11.2020
Int.Class A61K 47/60
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
56the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
59obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
60the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Appl.No 16821535 Applicant Nexlmmune, Inc. Inventor Bruce McCreedy

The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.

10.20200345854BISPECIFIC ANTIBODY CAPABLE OF BEING COMBINED WITH IMMUNE CELLS TO ENHANCE TUMOR KILLING CAPABILITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
US 05.11.2020
Int.Class A61K 47/59
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
56the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
59obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
Appl.No 16935679 Applicant BENHEALTH BIOPHARMACEUTIC (SHENZHEN) CO., LTD. Inventor Haoyang YU

The present invention provides a bispecific antibody capable of being combined with immune cells to enhance a targeting tumor killing capability, and a preparation method therefor and an application thereof. Antibodies and degradable nanoparticles are connected by using a chemical method, so as to make the one nanoparticle be connected to two or more antibody molecules at the same time, wherein one antibody can be specifically bound with immune cells, and the other antibody or the other antibodies can be specifically bound to tumor cells so as to achieve the effect of enhancing the capability of the immune cells for specifically killing tumor cells in a targeting way.